Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Traws Pharma, Inc.

NASDAQ: TRAW · Life Sciences · 3 alerts · CIK 1130598

Share price
$0.2600Close, Nov 16
Market cap
$4M
Shares outstanding
15.37MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Traws Pharma, Inc. filings on SEC EDGAR ↗

7:01 AM ET 8-K
Clinical Trial Data

Traws Pharma Clinical Trial Data

Traws Pharma announced final Phase 2a results for Ratutrelvir, showing symptom resolution comparable to PAXLOVID with no viral rebound and fewer treatment-related adverse events in COVID-19 patients. The company also completed a bridging study for Tivoxavir Marboxil (TXM), supporting its potential as a once-monthly influenza prophylactic agent.

5:19 PM ET 8-K
Capital Raise

Traws Pharma Capital Raise

Traws Pharma entered into a common stock purchase agreement with Roth Principal Investments for an equity line of credit of up to $50 million. The company has the right, but not the obligation, to sell shares to Roth over a 36-month period following the effectiveness of a registration statement. This facility provides the company with flexible access to capital to fund operations at its sole discretion.

Counterparty
Roth Principal Investments, LLC
Term
36 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.